Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · October 03, 2022

EASD 2022: Frailest Patients With Type 2 Diabetes Benefit Most From SGLT2 Inhibitors and GLP-1 Receptor Agonists Over DPP4 Inhibitors

These benefits are obtained without an increased risk of adverse events

PracticeUpdate Editorial Team

 

Further Reading